CD47 and myelodysplastic syndrome: Magrolimab, a CD47 inhibitor, was assessed in a phase 1b study either as single agent in R/R AML/MDS or in association with 5-AZA in untreated AML patients non-eligible for intensive chemotherapy and untreated MDS patients who are stratified as intermediate, high, or very high risk according to the Revised International Prognostic Scoring System (IPSS-R) (131).